Industry news

Biopharmaceutical Sector Leads the Way in Clinical Trial Data Sharing

Bill Chin / The Pharmaceutical Research and Manufacturers of America (PhRMA)

Effective and responsible sharing of clinical trial data continues to expand scientific discourse and discovery, as we have chronicled here on the Catalyst.

U.K. looks to FDA 'breakthrough' status for inspiration in regulatory revamp

Nick Paul Taylor / Fierce Biotech

The United Kingdom government has established the scope of the hotly anticipated review into the development and reimbursement of drugs. And the independent panel is being tasked with looking beyond the U.K.'s borders for inspiration, with an analysis of what can be learnt from FDA's "breakthrough" designation on its to-do list.

Google adds Tute database to burgeoning Genomics platform

Nick Paul Taylor / Fierce Biotech IT

Google ($GOOG) has added another publicly available database to its growing Genomics platform. The latest deal sees Google Genomics host Tute Genomics' repository of 8.5 billion annotations of genetic variants, giving users another resource to probe with the tech giant's growing arsenal of data integration tools.

Survey: Lack of device connectivity leads to medical errors and $30B+ annual cost

Stacy Lawrence / Fierce Medical Devices

The transcription of medical data from devices by nurses is a common source of medical errors that costs the U.S. healthcare system upward of $30 billion. That's according to a survey and other data assembled by a nonprofit medical research organization, the West Health Institute.

From Ancestry to Health to Drug Development

GenomeWeb

Consumer genetics firm 23andMe is getting in on the drug development business with the help of former Genentech executive Richard Scheller, as GenomeWeb has reported. 

The Five Essential Truths about Prescription Drug Spending

Robert Zirkelbach / Pharmaceutical Research and Manufacturers of America

Every day patients around the world are living healthier, more productive lives thanks to innovative medicines developed by biopharmaceutical companies.  Retail prescription medicines have consistently accounted for just 10 percent of United States health care spending and federal actuaries project this share will remain stable through the next decade. 

Biotech in China is built brick-by-brick, but more money would help, BeiGene's Oyler says

EJ Lane / FeircePharmaAsia

Chemistry and now world-class biology are joining hands in China in ways that will have a profound impact on biotechnology startups and established companies. But it is still early days for many and more money from venture capitalists or other funding sources is welcome, said John Oyler, co-founder and CEO of BeiGene and holder of the same title at his previous venture, BioDuro, which was sold to PPD.

Drug to slow down aging

The Times of India

Scientists have identified a new class of drugs that in animal models dramatically slows the aging process by alleviating symptoms of frailty , improving cardiac function and extending a healthy lifespan. 

16 March 2015

Clearside Biomedical, Inc. Reports Efficacy and Safety Results in Non-infectious Uveitis Using a Single Suprachoroidal Injection of Triamcinolone Acetonide

Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the efficacy and safety results from Clearside’s recently completed six-month Phase 1/2 clinical trial.

Physicians Deserve Timely Authoritative Risk Information For Medicines

Jeff Francer / The Pharmaceutical Research and Manufacturers of America (PhRMA)

A Washington Post article today inaccurately describes the Food and Drug Administration’s (FDA) proposed guidance on distributing peer-reviewed scientific and medical information to healthcare professionals.